CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.000
+0.080 (4.17%)
Nov 14, 2025, 4:00 PM EST - Market closed
CytoMed Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for CytoMed Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for CytoMed Therapeutics.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +150.00% | Oct 10, 2024 |
| Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +150.00% | Jun 11, 2024 |
| Benchmark | Benchmark | Buy Reiterates $5 | Buy | Reiterates | $5 | +150.00% | Dec 4, 2023 |
| Benchmark | Benchmark | Buy Initiates $5 | Buy | Initiates | $5 | +150.00% | Jul 21, 2023 |
Financial Forecast
Revenue This Year
530.40K
from 503.37K
Increased by 5.37%
Revenue Next Year
n/a
from 530.40K
EPS This Year
-0.17
from -0.22
EPS Next Year
n/a
from -0.17
Financial currency is SGD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 |
|---|---|
| High | 546,000 |
| Avg | 530,400 |
| Low | 509,600 |
Revenue Growth
| Revenue Growth | 2025 |
|---|---|
| High | 8.5% |
| Avg | 5.4% |
| Low | 1.2% |
EPS Forecast
| EPS | 2025 |
|---|---|
| High | -0.18 |
| Avg | -0.17 |
| Low | -0.17 |
EPS Growth
| EPS Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.